Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.05 USD -0.64% Market Closed
Market Cap: 967.8m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zymeworks Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Selling, General & Administrative
-$60.1m
CAGR 3-Years
-6%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.6B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.5B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.9B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-21%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
985.7m USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
21.21 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Selling, General & Administrative?
Selling, General & Administrative
-60.1m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Selling, General & Administrative amounts to -60.1m USD.

What is Zymeworks Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-8%

Over the last year, the Selling, General & Administrative growth was 30%. The average annual Selling, General & Administrative growth rates for Zymeworks Inc have been -6% over the past three years , -8% over the past five years .

Back to Top